BUZZ-Australia's Telix rises as US FDA accepts Pixclara drug application; Citi sees first revenue in 2027

Telix Pharmaceuticals Limited Sponsored ADR
Citigroup Inc.

Telix Pharmaceuticals Limited Sponsored ADR

TLX

0.00

Citigroup Inc.

C

0.00

Updates

** Telix Pharmaceuticals TLX.AX rises 6.9% to A$14.59, highest since December 11

** Stock on track for best day since March 10; top gainer on S&P/ASX 200 index .AXJO, which is down 0.4%

** Co says U.S. FDA accepts resubmitted New Drug Application for TLX101-Px (Pixclara)

** TLX101-Px is an investigational Positron emission tomography agent for imaging of glioma (brain cancer)

** Citi expects substantial revenue to first occur in 2027 upon Pixclara approval, launch

** Stock rated "buy" on avg; median PT is A$23.15, per data compiled by LSEG

** YTD, TLX up 30%


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.